Abbott

Global healthcare major Abbott has introduced an advanced drug-eluting coronary stent in India aimed at treating complex arterial blockages that pose challenges during angioplasty procedures. The device, part of the company’s next-generation XIENCE platform, is designed to enhance flexibility, precision and deliverability for cardiologists navigating intricate coronary anatomies. The launch arrives at a critical time as cardiovascular disease continues to surge across India due to rising lifestyle risks such as diabetes, hypertension and obesity.

In a pivotal move to enhance diabetes care across India, Abbott and MSD Pharmaceuticals have entered into a distribution partnership aimed at expanding access to key oral anti-diabetic medications. Under this agreement, Abbott will manage the distribution of MSD’s sitagliptin-based portfolio—including Januvia, Janumet, and Janumet XR—leveraging its vast reach and deep engagement in India's healthcare system.